.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) - Health
- Parenting
- Style and beauty
- Horoscopes
- Shopping
- Food
- Travel
- Autos
- Gift ideas
- Buying guides
- Amazon Spring Sale
- Amazon tech sales
- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Private Companies
- Research
- Personal Finance
- Videos
- Streaming Now
New on Yahoo
New on Yahoo
© 2025 All rights reserved.
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Humacyte price target lowered to $8 from $10 at BTIG
TipRanks
Sat, Mar 29, 2025, 10:40 AM
In This Article:
BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the target cut. The analyst views Humacyte’s early commercial traction as evidence of the “game-changing nature” of its Acellular Tissue Engineered Vessel.
Light Up your Portfolio with Spark:
-
Easily identify stocks' risks and opportunities.
-
Discover stocks' market position with detailed competitor analyses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HUMA:
Terms and Privacy Policy
Comments